Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck.

NCT04868162 is registered in ClinicalTrials.gov with Lepu Biopharma Co., Ltd. as lead sponsor.

NCT NCT04868162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04868162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck.
Lead sponsor
Lepu Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2021
Completion date
July 26, 2024
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic squamous cell carcinoma of head and neck